A clinically-grounded guide to understanding pancreatitis risk on semaglutide, what the latest 2025 and 2026 data actually show, and how to use these medications safely.
| Key TakeawaysAcute pancreatitis is a recognised but uncommon side effect of semaglutide, with randomised trials showing rates of roughly 0.2 cases per 100 patient-years in weight-loss trials.In January 2026, the UK MHRA strengthened warnings on all GLP-1 medicines after 1,296 Yellow Card reports of pancreatitis between 2007 and October 2025.If you develop severe, persistent stomach pain that radiates to the back, stop semaglutide and seek urgent medical care. |
If you are using or considering Ozempic, Wegovy, or Rybelsus, you deserve a clear, evidence-based answer on pancreatitis risk.
This guide walks you through what the data shows, what symptoms to watch for, how semaglutide compares with other GLP-1 medicines, and the steps to lower your risk.
1. What is pancreatitis, and why does it come up with semaglutide?
Pancreatitis is sudden inflammation of the pancreas, the organ behind your stomach that makes digestive enzymes and insulin.
When those enzymes start working inside the pancreas instead of the gut, they irritate the tissue, causing pain, swelling, and in severe cases, lasting damage.
Two forms matter most for this discussion. Acute pancreatitis is short-term and often resolves with hospital care. Chronic pancreatitis develops over time and can permanently affect digestion and blood sugar control.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It slows stomach emptying, signals fullness in the brain, and improves blood sugar control. Because the GLP-1 pathway is also active in the pancreas, regulators have monitored this drug class for pancreatic side effects since the earliest trials.
Per the U.S. Food and Drug Administration prescribing information for Ozempic, acute pancreatitis has been observed in patients on GLP-1 medicines and the label instructs clinicians to discontinue the drug promptly if pancreatitis is suspected. The Wegovy label carries the same warning, including reports of haemorrhagic and necrotising pancreatitis.
2. What does the latest research actually show about the risk?
The evidence is mixed, and that nuance matters. Randomised clinical trials suggest the absolute risk is low. Real-world observational studies have flagged a higher relative risk compared with non-GLP-1 weight-loss options.
Randomised trials: a low absolute signal
A 2024 meta-analysis published in Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis pooled 21 trials covering 34,721 patients and found no increased risk of acute pancreatitis with semaglutide overall (odds ratio 0.7, 95% CI 0.5 to 1.2).
Oral, low-dose injectable, and high-dose injectable formulations all showed similar findings.
In the pivotal Wegovy trials (the STEP programme), adjudicated pancreatitis occurred at approximately 0.2 cases per 100 patient-years, with no cases during a 2-year extension across both treatment and placebo groups, according to a 2025 review in PMC: Off-label ozempic and pancreatitis: legitimate concern or overblown fear?.
Real-world data: a higher relative signal in non-diabetic users
A widely cited 2023 study in JAMA: Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss analysed 16 million patient records and compared GLP-1 users (semaglutide and liraglutide) with bupropion-naltrexone users.
GLP-1 users had a 9-fold higher relative risk of pancreatitis (adjusted hazard ratio 9.09, 95% CI 1.25 to 66.00). Absolute case numbers were still small, roughly 1 to 2 percent across the studied GI events.
A larger 2025 PRISMA meta-analysis covering 62 randomised trials and 66,232 patients, published as Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists in Endocrinology, Diabetes & Metabolism, reported a modest but statistically significant overall increase (relative risk 1.44, 95% CI 1.09 to 1.89).
Though this signal disappeared when stratified by whether patients were on background diabetes medications.
MHRA 2026: strengthened warnings
In January 2026, the UK Medicines and Healthcare products Regulatory Agency issued a Drug Safety Update strengthening warnings across the entire GLP-1 class.
Between 2007 and October 2025, the MHRA received 1,296 Yellow Card reports of pancreatitis linked to GLP-1 medicines, including acute, chronic, haemorrhagic, and necrotising forms.
19 reports involved fatal outcomes, and 24 involved necrotising pancreatitis. For context, an estimated 25.4 million packs of GLP-1 medicines were dispensed in the UK over the past 5 years.
Table 1. Headline pancreatitis numbers from major studies and regulators
| Source | Finding | Year |
|---|---|---|
| **STEP weight-loss trials** (Wegovy) | Adjudicated pancreatitis approximately 0.2 cases per 100 patient-years; no cases in 2-year extension | 2021 to 2025 |
| Meta-analysis of 21 semaglutide trials | No increased risk vs placebo (OR 0.7, 95% CI 0.5 to 1.2) across 34,721 patients | 2024 |
| JAMA real-world study | 9-fold higher relative risk in non-diabetic weight-loss users vs bupropion-naltrexone (HR 9.09) | 2023 |
| Endocrinology, Diabetes & Metabolism meta-analysis | Modest increase across 62 trials, 66,232 patients (RR 1.44, 95% CI 1.09 to 1.89) | 2025 |
| MHRA Yellow Card data (UK) | 1,296 pancreatitis reports across 25.4 million packs dispensed; 19 fatal | 2007 to 2025 |
The honest interpretation: pancreatitis is rare on semaglutide, but it does happen, and post-marketing data show some cases are severe.
The risk-benefit balance shifts depending on why you are taking the drug, whether for type 2 diabetes, established obesity, or aesthetic weight loss in an otherwise healthy person.
3. What pancreatitis symptoms should you watch for on semaglutide?
The single most important symptom is severe, persistent abdominal pain that radiates to your back. Per both the FDA label and the MHRA, this is the warning sign that should prompt you to stop the medication and seek urgent medical attention.
Mild nausea, occasional indigestion, and short-lived stomach upset are common GLP-1 side effects, especially during dose escalation.
Pancreatitis presents differently. The pain is sharper, more persistent, and is usually accompanied by other red flags.
Table 2. How to distinguish typical GLP-1 side effects from possible pancreatitis
| Common GLP-1 side effect | Possible pancreatitis warning sign |
|---|---|
| **Mild to moderate nausea**, especially after dose increase | **Severe, persistent abdominal pain** in the upper belly that lasts hours and does not ease |
| Occasional vomiting that settles within hours | **Vomiting that does not stop** and is paired with severe pain |
| Indigestion, bloating, gas | **Pain that radiates from the abdomen to the back**, often described as boring or deep |
| Constipation or diarrhoea | **Fever, chills, or yellowing of the eyes** (possible jaundice) alongside pain |
| Reduced appetite | Rapid heart rate, light-headedness, or feeling severely unwell |
If pancreatitis is suspected, the official FDA guidance is clear: stop the medication promptly, contact your doctor, and do not restart if pancreatitis is confirmed.
Diagnostic confirmation usually involves blood tests measuring amylase and lipase at three times the upper limit of normal, along with imaging.
4. How does semaglutide compare with other GLP-1 medicines?
The FDA pancreatitis warning is a class-wide warning. It applies to all approved GLP-1 receptor agonists and dual GLP-1/GIP medicines, not just semaglutide.
That includes liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide, and tirzepatide (Mounjaro, Zepbound).
When the 2025 Endocrinology, Diabetes & Metabolism meta-analysis broke down the data by individual drug, the modest increased relative risk was not statistically significant for any single molecule on its own, suggesting the signal is class-related rather than semaglutide-specific.
Table 3. Pancreatitis warning status across GLP-1 medicines
| Medicine | Active ingredient | Pancreatitis labelling |
|---|---|---|
| **Ozempic** (injectable) | Semaglutide 0.25 to 2 mg weekly | Discontinue if pancreatitis suspected; do not restart if confirmed |
| **Wegovy** (injectable) | Semaglutide up to 2.4 mg weekly | Same class warning; haemorrhagic and necrotising cases reported |
| **Rybelsus** (oral) | Semaglutide 3, 7, or 14 mg daily | Same class warning; pancreatitis reported in trials |
| Saxenda / Victoza | Liraglutide | Same class warning; daily injection |
| Mounjaro / Zepbound | Tirzepatide (GLP-1 + GIP) | Same class warning; MHRA 2026 update applies |
| Trulicity | Dulaglutide | Same class warning |
5. Who is at higher risk of pancreatitis on semaglutide?
Pancreatitis risk is not distributed evenly. Several baseline factors increase your background risk regardless of whether you take semaglutide, and these matter even more once you start a GLP-1 medicine.
Gallstones are the single most common cause of acute pancreatitis. A 2024 PubMed analysis from Kashmir, India found that gallstones accounted for 47.7 percent of acute pancreatitis admissions, rising from 31 percent in 2015 to 52.4 percent by 2019.
Rapid weight loss can itself trigger gallstone formation, which is one reason GLP-1 medicines and pancreatitis sometimes appear linked even when the drug is not the direct cause.
Table 4. Baseline factors that increase pancreatitis risk
| Risk factor | Why it matters |
|---|---|
| History of pancreatitis | Strongest predictor of recurrence; FDA labelling lists this as a precaution for restart |
| Known gallstones | Most common single cause of acute pancreatitis; rapid weight loss can worsen this |
| Heavy alcohol use | Independent cause of both acute and chronic pancreatitis |
| **Very high triglycerides** (above 1,000 mg/dL) | Causes hypertriglyceridemic pancreatitis |
| Family history of pancreatitis or pancreatic disease | Suggests possible genetic susceptibility; under MHRA investigation |
| Existing gallbladder disease or biliary sludge | Increases risk of stone-related obstruction |
The MHRA and Genomics England are also running an active Yellow Card Biobank investigation into whether specific genetic variants make certain people more vulnerable to GLP-1-related pancreatitis. Results are pending, but the existence of the investigation reflects how regulators are taking the signal seriously.
6. Why this matters for users in India right now
Semaglutide use has expanded rapidly across Indian metros. Novo Nordisk launched Wegovy in India in June 2025, and Eli Lilly’s Mounjaro (tirzepatide) launched in March 2025.
The semaglutide patent expires in India in March 2026, with multiple domestic manufacturers including Sun Pharma, Dr Reddy’s, Cipla, and Biocon preparing generic versions.
Three points deserve attention in the local context:
- Gallstone disease is common in India, and the population-level shift toward rapid weight loss with GLP-1 medicines means more clinicians are likely to see this combination.
- Off-label prescribing of Ozempic for weight loss, despite Ozempic being approved only for type 2 diabetes, continues in private practice. This matters because risk-benefit calculations shift when the indication is cosmetic rather than medical.
- Generic semaglutide entering the market will increase access but also expose larger populations to the same safety considerations. The MHRA-strengthened warnings are likely to influence Indian regulatory communication in the months ahead.
Always use semaglutide under a qualified physician’s supervision. Drugs from informal channels, unbranded vials, or online sellers carry additional risks beyond pancreatitis, including dosing errors and contamination.
7. How can you lower your pancreatitis risk before and during treatment?
A careful evaluation before starting semaglutide is the most important step. The conversations to have with your doctor are practical and specific.
Before starting semaglutide
- Share your full medical history, especially any past episode of pancreatitis, even if it was years ago.
- Mention known gallstones, gallbladder disease, or a history of jaundice.
- Disclose alcohol use honestly, including average weekly intake.
- Ask about a baseline fasting triglyceride test if you have not had one recently.
- Discuss family history of pancreatitis or pancreatic cancer.
During treatment
- Follow the recommended dose-escalation schedule rather than self-adjusting upward.
- Minimise or avoid alcohol while on the medication, particularly during dose increases.
- Stay well hydrated, especially if nausea or reduced food intake is affecting you.
- Recognise warning signs early. Severe, persistent upper abdominal pain that travels to the back is the signal to stop the drug and seek care.
- Do not restart semaglutide on your own if you have stopped due to suspected pancreatitis. The decision to restart is a medical one.
8. What should you do if you suspect pancreatitis?
Treat suspected pancreatitis as a medical emergency. The FDA labelling, MHRA guidance, and clinical consensus all point in the same direction.
Table 5. Suspected pancreatitis: the action ladder
| Step | What to do |
|---|---|
| 1. Stop semaglutide | Do not take the next scheduled dose; the FDA label requires prompt discontinuation if pancreatitis is suspected |
| 2. Seek urgent care | Go to a hospital emergency department, not a GP clinic, if pain is severe and persistent |
| 3. Ask for the right tests | Serum lipase and amylase, complete blood count, liver function tests, and abdominal imaging (ultrasound or CT) |
| 4. Disclose your medication | Tell the treating doctor exactly which GLP-1 you are on, the dose, how long you have used it, and the date of your last injection |
| 5. Do not restart on your own | If pancreatitis is confirmed, the FDA label says do not restart semaglutide; if pancreatitis is ruled out, restart only under physician guidance |
9. The Bottom Line
| Bottom LinePancreatitis is a recognised but uncommon side effect of semaglutide. Randomised trials suggest a low absolute risk, while real-world data show a higher relative risk in non-diabetic users compared with non-GLP-1 weight-loss options. The MHRA’s January 2026 update reinforces that severe cases, though rare, do occur.The practical takeaway: know your baseline risk factors, watch for severe abdominal pain that radiates to the back, and stop the medication and seek urgent care if you suspect pancreatitis. Used under proper medical supervision, semaglutide remains a clinically valuable option for the right patients. |
Frequently Asked Questions
Does semaglutide increase the risk of pancreatitis?
Randomised trials show a low absolute risk, with rates around 0.2 cases per 100 patient-years in weight-loss trials. Real-world studies have flagged a higher relative risk in non-diabetic weight-loss users compared with bupropion-naltrexone.
The overall absolute risk remains uncommon, but the FDA and MHRA both list pancreatitis as a recognised possible side effect.
What are pancreatitis symptoms to watch for on semaglutide?
The key warning sign is severe, persistent upper abdominal pain that radiates to the back, often with nausea and vomiting that does not settle.
Fever, chills, or yellowing of the eyes alongside pain are additional red flags. If these occur, stop semaglutide and seek urgent medical care.
Is Wegovy more risky for pancreatitis than Ozempic?
Both medicines contain semaglutide and carry the same class-wide pancreatitis warning. Wegovy uses a higher dose (up to 2.4 mg weekly) for weight management, while Ozempic uses lower doses for type 2 diabetes.
Current evidence suggests dose differences do not meaningfully change the pancreatitis signal, but always discuss your specific risk with your prescriber.
Can I take semaglutide if I have had pancreatitis before?
Semaglutide has not been specifically studied in patients with a history of pancreatitis, and the FDA label advises clinicians to consider this when prescribing.
Many specialists avoid GLP-1 medicines in patients with prior pancreatitis. This is a decision to make with a gastroenterologist or endocrinologist, not on your own.
Should I stop semaglutide for mild stomach pain?
Mild, short-lived nausea or indigestion is a common GLP-1 side effect, especially during dose escalation, and usually does not require stopping the medication.
Severe, persistent pain that radiates to the back is different and should prompt you to stop the drug and seek urgent care. When in doubt, contact your doctor.
| Medical DisclaimerThis article is for general educational purposes only and does not replace personalised medical advice. Decisions about starting, stopping, or changing semaglutide or any GLP-1 medicine should be made with a qualified healthcare professional who knows your full medical history. If you suspect pancreatitis or any medical emergency, seek urgent care immediately. |
